Asian Pacific journal of cancer prevention : APJCP · 2026
miR-1294 Upregulation as a Diagnostic Biomarker for Cholangiocarcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Supradit Kittiya, Phanaksri Teva, Prasopdee Sattrachai, Tangphatsornruang Sithichoke, Sangsrakru Duangjai, Wongprasert Kanokpan, Pholhelm Montinee, Butthongkomvong Kritiya, Kulsantiwong Jutharat, Kunjantarachot Anthicha, Thitapakorn Veerachai
Аннотация
OBJECTIVE: To investigate plasma miR-1294 levels in cholangiocarcinoma (CCA) patients compared with healthy individuals and Opisthorchis viverrini-infected subjects.
METHODS: To assess its potential as a plasma-based diagnostic biomarker, plasma samples were collected and total RNA was extracted from 15 healthy controls (HC), 12 O. viverrini (OV)-infected individuals, and 33 patients with CCA. miR-1294 expression was quantified using RT-qPCR (MiRXES).
RESULTS: Relative expression analysis demonstrated a significant upregulation of plasma miR-1294 in patients with CCA compared with both HC and OV groups (P < 0.0001). Receiver operating characteristic (ROC) curve analysis showed that miR-1294 discriminated CCA from non-CCA subjects, yielding an area under the curve (AUC) of 0.8676, with a specificity of 96.30% and a sensitivity of 63.64%.
CONCLUSION: The upregulation of plasma miR-1294 was investigated in this study. Despite these promising findings, the moderate sensitivity suggests that miR-1294 alone may not be sufficient as a standalone diagnostic marker. Nevertheless, its high specificity and non-invasive detectability highlight its potential utility as a complementary biomarker, particularly in combination with other diagnostic indicators for improved detection of CCA.
METHODS: To assess its potential as a plasma-based diagnostic biomarker, plasma samples were collected and total RNA was extracted from 15 healthy controls (HC), 12 O. viverrini (OV)-infected individuals, and 33 patients with CCA. miR-1294 expression was quantified using RT-qPCR (MiRXES).
RESULTS: Relative expression analysis demonstrated a significant upregulation of plasma miR-1294 in patients with CCA compared with both HC and OV groups (P < 0.0001). Receiver operating characteristic (ROC) curve analysis showed that miR-1294 discriminated CCA from non-CCA subjects, yielding an area under the curve (AUC) of 0.8676, with a specificity of 96.30% and a sensitivity of 63.64%.
CONCLUSION: The upregulation of plasma miR-1294 was investigated in this study. Despite these promising findings, the moderate sensitivity suggests that miR-1294 alone may not be sufficient as a standalone diagnostic marker. Nevertheless, its high specificity and non-invasive detectability highlight its potential utility as a complementary biomarker, particularly in combination with other diagnostic indicators for improved detection of CCA.